01:48 PM EST, 11/04/2025 (MT Newswires) -- Qiagen ( QGEN ) agreed to acquire biotechnology firm Parse Biosciences for an upfront payment of $225 million in cash, plus up to $55 million in milestone payments tied to multiyear performance targets.

The transaction is expected to close in December, Qiagen ( QGEN ) said Tuesday in a statement.

Qiagen ( QGEN ) said the deal will be dilutive to adjusted earnings by $0.04 per share in 2026 and accretive beginning in 2028. Parse is projected to contribute $40 million in sales in 2026, with double-digit growth expected in subsequent years.

The acquisition is intended to expand Qiagen's ( QGEN ) Sample Technologies portfolio into the single-cell sequencing market and accelerate growth in its Digital Insights bioinformatics business, according to the statement.

Price: 44.79, Change: -0.89, Percent Change: -1.95